Meridian Investment Counsel’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.42M | Sell |
25,506
-825
| -3% | -$177K | 1.38% | 10 |
|
|
2026
Q1 | $5.73M | Sell |
26,331
-220
| -0.8% | -$48.8K | 1.36% | 10 |
|
|
2025
Q4 | $6.07M | Sell |
26,551
-50
| -0.2% | -$11.4K | 1.46% | 8 |
|
|
2025
Q3 | $6.16M | Sell |
26,601
-250
| -0.9% | -$50.9K | 1.52% | 10 |
|
|
2025
Q2 | $4.98M | Buy |
26,851
+282
| +1% | +$52.4K | 1.36% | 14 |
|
|
2025
Q1 | $5.57M | Sell |
26,569
-325
| -1% | -$63.2K | 1.64% | 8 |
|
|
2024
Q4 | $4.78M | Sell |
26,894
-940
| -3% | -$173K | 1.43% | 11 |
|
|
2024
Q3 | $5.5M | Sell |
27,834
-700
| -2% | -$131K | 1.66% | 8 |
|
|
2024
Q2 | $4.89M | Sell |
28,534
-174
| -0.6% | -$28.8K | 1.55% | 9 |
|
|
2024
Q1 | $5.23M | Sell |
28,708
-661
| -2% | -$114K | 1.74% | 10 |
|
|
2023
Q4 | $4.55M | Sell |
29,369
-68
| -0.2% | -$9.91K | 1.56% | 11 |
|
|
2023
Q3 | $4.39M | Sell |
29,437
-1,035
| -3% | -$152K | 1.64% | 10 |
|
|
2023
Q2 | $4.11M | Hold |
30,472
| – | – | 1.46% | 12 |
|
|
2023
Q1 | $4.86M | Sell |
30,472
-25
| -0.1% | -$3.82K | 1.84% | 9 |
|
|
2022
Q4 | $4.93M | Buy |
30,497
+17
| +0.1% | +$2.61K | 1.97% | 8 |
|
|
2022
Q3 | $4.09M | Sell |
30,480
-100
| -0.3% | -$14.3K | 1.82% | 11 |
|
|
2022
Q2 | $4.68M | Sell |
30,580
-217
| -0.7% | -$33.2K | 1.93% | 9 |
|
|
2022
Q1 | $4.99M | Sell |
30,797
-495
| -2% | -$71.9K | 1.74% | 9 |
|
|
2021
Q4 | $4.24M | Sell |
31,292
-1,195
| -4% | -$141K | 1.41% | 16 |
|
|
2021
Q3 | $3.5M | Sell |
32,487
-83
| -0.3% | -$9.48K | 1.27% | 20 |
|
|
2021
Q2 | $3.67M | Buy |
32,570
+231
| +0.7% | +$26K | 1.29% | 18 |
|
|
2021
Q1 | $3.5M | Buy |
32,339
+325
| +1% | +$34.8K | 1.35% | 17 |
|
|
2020
Q4 | $3.43M | Buy |
32,014
+295
| +0.9% | +$28.3K | 1.45% | 16 |
|
|
2020
Q3 | $2.78M | Sell |
31,719
-1,065
| -3% | -$100K | 1.35% | 20 |
|
|
2020
Q2 | $3.22M | Buy |
32,784
+154
| +0.5% | +$13.6K | 1.64% | 14 |
|
|
2020
Q1 | $2.49M | Buy |
32,630
+3,665
| +13% | +$312K | 1.61% | 13 |
|
|
2019
Q4 | $2.56M | Buy |
28,965
+300
| +1% | +$24.9K | 1.27% | 23 |
|
|
2019
Q3 | $2.17M | Buy |
28,665
+3,475
| +14% | +$238K | 1.18% | 23 |
|
|
2019
Q2 | $1.83M | Buy |
25,190
+245
| +1% | +$19.3K | 1.01% | 29 |
|
|
2019
Q1 | $2.01M | Sell |
24,945
-225
| -0.9% | -$18.4K | 1.17% | 28 |
|
|
2018
Q4 | $2.32M | Sell |
25,170
-875
| -3% | -$76.9K | 1.52% | 16 |
|
|
2018
Q3 | $2.46M | Sell |
26,045
-50
| -0.2% | -$4.74K | 1.35% | 20 |
|
|
2018
Q2 | $2.42M | Sell |
26,095
-70
| -0.3% | -$6.84K | 1.37% | 16 |
|
|
2018
Q1 | $2.48M | Sell |
26,165
-375
| -1% | -$41.2K | 1.4% | 17 |
|
|
2017
Q4 | $2.57M | Buy |
26,540
+17
| +0.1% | +$1.6K | 1.39% | 17 |
|
|
2017
Q3 | $2.36M | Hold |
26,523
| – | – | 1.36% | 19 |
|
|
2017
Q2 | $1.92M | Buy |
26,523
+233
| +0.9% | +$15.7K | 1.15% | 25 |
|
|
2017
Q1 | $1.71M | Buy |
26,290
+1,475
| +6% | +$92.7K | 1.05% | 29 |
|
|
2016
Q4 | $1.55M | Buy |
24,815
+250
| +1% | +$15.3K | 1.04% | 30 |
|
|
2016
Q3 | $1.55M | Sell |
24,565
-1,000
| -4% | -$64.7K | 1.04% | 31 |
|
|
2016
Q2 | $1.58M | Buy |
25,565
+900
| +4% | +$54.8K | 1.08% | 30 |
|
|
2016
Q1 | $1.41M | Sell |
24,665
-500
| -2% | -$27.9K | 0.99% | 33 |
|
|
2015
Q4 | $1.49M | Buy |
25,165
+100
| +0.4% | +$5.76K | 1.1% | 28 |
|
|
2015
Q3 | $1.36M | Buy |
25,065
+725
| +3% | +$47.2K | 1.12% | 29 |
|
|
2015
Q2 | $1.64M | Sell |
24,340
-650
| -3% | -$42.4K | 1.17% | 28 |
|
|
2015
Q1 | $1.46M | Buy |
+24,990
| New | +$1.51M | 1.02% | 31 |
|
Other funds holding ABBV
ECSS
ATO
Meridian Investment Counsel's ABBV Position: Q2 2026 in Review
Meridian Investment Counsel reduced its AbbVie (ABBV) stake by 3.1% in Q2 2026, selling an estimated $177K and leaving 25,506 shares worth $6.42M. The position accounts for 1.38% of the portfolio, ranked #10.
Meridian Investment Counsel first reported a position in ABBV in Q1 2015 and has held it in 46 quarters since. 1,844 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Meridian Investment Counsel held 25,506 shares of AbbVie worth $6.42M as of Q2 2026.
- Meridian Investment Counsel sold 825 AbbVie shares in Q2 2026, an estimated $177K.
- AbbVie made up 1.38% of Meridian Investment Counsel's portfolio in Q2 2026, its #10 holding.
- Meridian Investment Counsel first reported a position in AbbVie in Q1 2015 and has held it in 46 quarters since.
- 1,844 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Meridian Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.